AI Summary

Novartis’ failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry’s biggest drug races. The setback casts doubt on the company’s cholesterol‑lowering candidate, which was competing with rival treatments from U.S. heavyweights Amgen and Eli Lilly. The trial’s outcome suggests that the race to develop a superior cholesterol drug may face unexpected hurdles, prompting scrutiny of the competing approaches from the American firms.

AI summaries can be wrong sometimes—always verify important details using the source article.